Lactobacillus Jensenii 1153-1666 - Osel
Alternative Names: Genetically-modified LBPs - Osel; MucoCept - Osel; MucoCept LBPs - Osel; MucoCept-CVN; Research programme: topical microbicides - OselLatest Information Update: 25 Sep 2025
At a glance
- Originator Osel Inc
- Class Anti-infectives; Antivirals; Bacteria
- Mechanism of Action HIV fusion inhibitors; Virus attachment inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical HIV infections
- Discontinued Bacterial vaginosis
Most Recent Events
- 25 Sep 2025 Discontinued - Preclinical for Bacterial vaginosis in USA (Vaginal) prior to September 2025 (Osel Pipeline, September 2025)
- 22 Sep 2025 Osel plans a phase I trial for HIV infections (Prevention) in USA (Vaginal) (NCT07181486)
- 18 Sep 2025 Lactobacillus Jensenii 1153-1666 is still in preclinical study for HIV infection prevention in USA (Osel pipeline, September 2025)